Liquidia Corp (LQDA): Operating Income
-$51.38M
Year ended 2025-12-31
$168.57M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$51.38M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$121.29M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$73.38M | n/m | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | -$38.77M | n/m | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | -$33.80M | n/m | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | -$59.09M | n/m | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | -$46.82M | n/a | 2021-03-25, From 2019-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Liquidia Corp (LQDA) | 2025-12-31 | -$51.38M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$72.84M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $49.11M | +150.6% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$90.71M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$273.08M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$159.99M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$36.81M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $6.10M | -50.0% |
Compare LQDA, HRTX, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗